SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amc - Quaterly Results

30 May 2024 Evaluate
Revenue showed a marginal decline at Rs. 1112.60 millions. For the quarter ended March 2024, as compared to corresponding quarter of last year.The Net Loss for the quarter ended March 2024 is Rs. -311.20 millions as compared to Net Loss of Rs. -102.30 millions of corresponding quarter ended March 2023The company reported a degrowth in operating Profit to 83.60 millions from 211.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1112.60 1131.30 -1.65 3273.50 4025.50 -18.68 3273.50 4025.50 -18.68
Other Income -32.10 147.90 -121.70 630.50 521.60 20.88 630.50 521.60 20.88
PBIDT 83.60 211.40 -60.45 698.50 599.20 16.57 698.50 599.20 16.57
Interest 158.70 170.30 -6.81 681.90 579.20 17.73 681.90 579.20 17.73
PBDT -75.10 41.10 -282.73 -13.90 0.00 0.00 -13.90 0.00 0.00
Depreciation 261.20 234.50 11.39 1016.10 962.00 5.62 1016.10 962.00 5.62
PBT -336.30 -193.40 73.89 -1030.00 -962.00 7.07 -1030.00 -962.00 7.07
TAX -25.10 -91.10 -72.45 -265.90 -373.30 -28.77 -265.90 -373.30 -28.77
Deferred Tax -135.70 -91.10 48.96 -376.50 -373.30 0.86 -376.50 -373.30 0.86
PAT -311.20 -102.30 204.20 -764.10 -588.70 29.79 -764.10 -588.70 29.79
Equity 313.60 313.60 0.00 313.60 313.60 0.00 313.60 313.60 0.00
PBIDTM(%) 7.51 18.69 -59.79 21.34 14.89 43.35 21.34 14.89 43.35

Dishman Carbogen Amc Share Price

168.60 -2.00 (-1.17%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×